首页> 美国卫生研究院文献>Theranostics >A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
【2h】

A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA

机译:一种基于金纳米棒的纳米载体用于阿霉素和siRNA共同递送的胰腺腺癌的光驱动疗法。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment.
机译:在这项工作中,我们报告了基于聚电解质聚合物的基于金纳米棒(AuNRs)的纳米载体的工程设计,该载体能够向Panc-1癌细胞共同递送小干扰RNA(siRNA)和抗癌药物阿霉素(DOX),以实现以下作用:化学和siRNA介导的突变K-Ras基因沉默治疗。通过用665 nm的光照射纳米复合物制剂,通过促进的siRNA和DOX释放的协同组合,观察到了优异的抗癌效果。我们的抗肿瘤研究表明,AuNRs纳米复合物配方与665 nm光处理的协同效应能够将体内肿瘤体积的生长速率抑制90%。抗肿瘤作用归因于K-Ras基因的失活,从而在处理过的Panc-1细胞中引起深刻的合成(S)停滞。我们的研究表明,经纳米复合制剂S期处理的Panc-1细胞的百分比确定为35%,比未经任何处理的Panc-1细胞高出17%。结合化学疗法,RNA沉默和NIR窗口光介导的疗法,这里开发的纳米疗法配方将被视为临床研究中下一步自然要采取的步骤,以改善胰腺腺癌的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号